Vitamin K Antagonist Use and Fracture
We read with interest the article by Fiordellisi and colleagues, who reported findings of a systematic review and meta-analysis on the association between vitamin K antagonist (VKA) use and fracture.1 The results provide an important contribution to better understand the risk of fractures associated with VKA use, which is still controversial and not well described in clinical practice.
Compliance with Ethical Standards
Conflict of Interest
ICKW has received research funding outside the submitted work from the Hong Kong Research Grants Council, the Hong Kong Health and Medical Research Fund, Bristol-Myers Squibb, Pfizer, Janssen, and Bayer; KKCM is supported by the CW Maplethorpe Fellowship and has received personal fees outside the submitted work from IQVIA Holdings. No other disclosures were reported.
- 3.Norby FL, Bengtson LGS, Lutsey PL, Chen LY, MacLehose RF, Chamberlain AM, et al. Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation. BMC Cardiovasc Disord. 2017;17(1).Google Scholar